Analysis of adverse events of bevacizumab-containing systemic chemotherapy for metastatic colorectal cancer in Japan

Anticancer Research

Volumn 34, Issue 4, 2014, Pages 2035-2040

  Isobe, Taichi ^a   Uchino, Keita ^b   Makiyama, Chinatsu ^a   Ariyama, Hiroshi ^a   Arita, Shuji ^a,f   Tamura, Shingo ^a   Komoda, Masato ^b   Kusaba, Hitoshi ^a   Shirakawa, Tsuyoshi ^c   Esaki, Taito ^c   Mitsugi, Kenji ^d   Takaishi, Shigeo ^e   Akashi, Koichi ^a   Baba, Eishi ^f  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^c NATIONAL KYUSHU CANCER CENTER   (Japan)

^d HAMANOMACHI HOSPITAL   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

^f KYUSHU UNIVERSITY   (Japan)

Author keywords

Adverse events; Bevacizumab; Chemotherapy; Colorectal cancer

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANOREXIA; ARTERIAL THROMBOEMBOLISM; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; GINGIVA BLEEDING; HUMAN; HYPERTENSION; JAPAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; METASTATIC COLORECTAL CANCER; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIMARY TUMOR; PROTEINURIA; RISK FACTOR; STOMACH PAIN; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT REFUSAL; TREATMENT RESPONSE; VERY ELDERLY; WOUND HEALING IMPAIRMENT; ADVERSE EVENTS; CHEMOTHERAPY; COLORECTAL CANCER; COLORECTAL TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADVERSE EVENTS; BEVACIZUMAB; CHEMOTHERAPY; COLORECTAL CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902283314     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M and Ferrara N: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57: 4593-4599, 1997.
2. McCrudden KW, Hopkins B, Frischer J, Novikov A, Huang J, Kadenhe A, New T, Yokoi A, Yamashiro DJ, Kandel JJ and Middlesworth W: Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis. J Pediatr Surg 38: 308-314, 2003.
3. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N and Jain RK: Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 93: 14765-14770, 1996.
4. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY and Jain RK: Direct evidence that the VEGF-specific antibody BV has antivascular effects in human rectal cancer. Nat Med 10: 145-147, 2004.
5. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F: BV plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
6. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F and Cassidy J: BV in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013-2019, 2008.
7. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd and Eastern Cooperative Oncology Group Study E3200: BV in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539-1544, 2007.
8. Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, von Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S, on behalf of the ML18147 Study Investigators: Continuation of BV after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14: 29-37, 2013.
9. Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, Ashby MA, Dong W, Sugrue MM, Grothey A; Investigators of the BRiTE study: Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 14: 862-870, 2009.
10. Tamiya A, Yamazaki K, Boku N, Machida N, Kojima T, Taku K, Yasui H, Fukutomi A, Hironaka S and Onozawa Y: Safety of BV treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients. Int J Clin Oncol 14: 513-517, 2009.
11. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J and Hurwitz H: Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and BV. J Natl Cancer Inst 99: 1232-1239, 2007.
12. International Consortium for Blood Pressure Genome-Wide Association Studies: Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 478: 103-109, 2011.